| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HDI.12555 |
| P8608 | Fatcat ID | release_kd6ga3yf6ndmtgwgsxbphtkzaq |
| P698 | PubMed publication ID | 28328144 |
| P50 | author | Paolo Ferrari | Q43269545 |
| John K. Olynyk | Q37830523 | ||
| P2093 | author name string | Ganesh Ramanathan | |
| P2860 | cites work | Sudden cardiac death in hemodialysis patients: an in-depth review | Q37865761 |
| KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. | Q38124594 | ||
| Iron toxicity: relevance for dialysis patients | Q38156094 | ||
| The safety of intravenous iron preparations: systematic review and meta-analysis | Q38311772 | ||
| Annual Iron Loss Associated with Hemodialysis | Q40905623 | ||
| Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients | Q42218133 | ||
| Hepcidin regulation: ironing out the details | Q42734886 | ||
| Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study | Q43433524 | ||
| Time-dependent associations between iron and mortality in hemodialysis patients | Q43818759 | ||
| Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis | Q43879335 | ||
| Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis | Q44264773 | ||
| Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement | Q45012876 | ||
| Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients | Q45133974 | ||
| Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients | Q46217820 | ||
| Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference | Q46240911 | ||
| Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation | Q46442596 | ||
| Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease | Q46474866 | ||
| The DOPPS Practice Monitor for US dialysis care: trends through August 2011. | Q47805384 | ||
| Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. | Q47915626 | ||
| KHA-CARI Guideline: use of iron in chronic kidney disease patients | Q47952749 | ||
| Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron | Q49198580 | ||
| Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. | Q50709357 | ||
| The Content of Reticulocyte Hemoglobin and Serum Concentration of the Soluble Transferrin Receptor for Diagnostics of Anemia in Chronically Hemodialyzed Patients. | Q51506061 | ||
| Non-invasive assessment of hepatic iron stores by MRI. | Q51999923 | ||
| Hepatic iron concentration and total body iron stores in thalassemia major. | Q52075941 | ||
| Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. | Q52866412 | ||
| Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q53102532 | ||
| Factors predicting erythropoietin resistance among maintenance hemodialysis patients. | Q53653496 | ||
| The adverse effect of iron repletion on the course of certain infections | Q54956692 | ||
| Diagnostic value of iron indices in hemodialysis patients receiving epoetin | Q58118268 | ||
| Hereditary hemochromatosis in the post-HFE era | Q24646056 | ||
| Safety concerns about intravenous iron therapy in patients with chronic kidney disease | Q26764881 | ||
| Hepcidin: regulation of the master iron regulator | Q26800198 | ||
| Identification of erythroferrone as an erythroid regulator of iron metabolism | Q28240988 | ||
| Hepcidin in human iron disorders: diagnostic implications | Q28250198 | ||
| A randomized controlled study of iron supplementation in patients treated with erythropoietin | Q28296498 | ||
| Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality | Q30839550 | ||
| Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial | Q34182887 | ||
| Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major | Q34331274 | ||
| Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. | Q34333701 | ||
| Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease | Q34497292 | ||
| Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients | Q34506972 | ||
| Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients | Q35041088 | ||
| Iron requirements in hemodialysis | Q35633349 | ||
| MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients | Q35848072 | ||
| Single spin-echo proton transverse relaxometry of iron-loaded liver | Q35938087 | ||
| Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection | Q36123593 | ||
| Liver iron transport | Q36177913 | ||
| Iron overload in the liver diagnostic and quantification | Q36682433 | ||
| Assessing iron status: beyond serum ferritin and transferrin saturation | Q36910512 | ||
| The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? | Q36910516 | ||
| The regulation of cellular iron metabolism | Q36974377 | ||
| Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. | Q37042142 | ||
| R2* magnetic resonance imaging of the liver in patients with iron overload | Q37201858 | ||
| Hepcidin--a potential novel biomarker for iron status in chronic kidney disease | Q37211057 | ||
| Iron in arterial plaque: modifiable risk factor for atherosclerosis | Q37213378 | ||
| Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients | Q37214510 | ||
| Testing the iron hypothesis in a mouse model of atherosclerosis | Q37430727 | ||
| Hepcidin for clinicians | Q37531547 | ||
| P304 | page(s) | S58-S67 | |
| P577 | publication date | 2017-03-22 | |
| P1433 | published in | Hemodialysis International | Q15757113 |
| P1476 | title | Diagnosing and preventing iron overload | |
| P478 | volume | 21 Suppl 1 |
| Q58700150 | Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease |
| Q58793901 | Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice |
| Q52381914 | Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders. |
Search more.